Clinical trial
A Phase II Study of Perifosine in Patients With Relapsed/Refractory…
NCT00398710 · AEterna Zentaris, Industry · Completed
Key facts
| NCT number | NCT00398710 |
|---|---|
| Title | A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia |
| Official title | A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia |
| Lead sponsor | AEterna Zentaris, Industry |
| Collaborators | Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenström's Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Perifosine |
| Enrollment | 37 |
| Start date | Oct 1, 2006 |
| Primary completion | Aug 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Nov 14, 2006 |
| Last update posted | Mar 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: